Allogeneic CAR T-cells patented by Celyad

October 26, 2015 News BioVox

Celyad obtained a patent relating to allogeneic Chimeric Antigen Receptor (CAR) T-cells. CAR T-cells are T-cells, which are engineered to better recognize and fight cancerous cells. The use of allogeneic CAR T-cells in comparison to autologous cells, allows the development and manufacturing of “off-the-shelf” treatments for several diseases.

Learn more about the CAR T-cell technology in BioVox’ insight article about this topic.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter